An Open-Label Phase IB/II Study of Magrolimab in Combination With Azacitidine and Venetoclax for the Treatment of Patients With Acute Myeloid Leukemia (AML)
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Magrolimab (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2025 Status changed from suspended to discontinued.
- 06 Feb 2025 Planned End Date changed from 31 Dec 2024 to 28 Feb 2026.
- 06 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 28 Feb 2026.